Tailored Antigens, Leaner Workflows: Accelerating Therapeutic Antibody and ADC Discovery

Join us for a breakfast ecosystem at the PSCC, bringing together researchers, biotech professionals, and industry experts to discuss the latest advances in therapeutic antibody and antibody-drug conjugate (ADC) discovery.

This session will explore how tailored antigen design and leaner development workflows can significantly accelerate the path from target identification to therapeutic candidates, a critical challenge in oncology drug development.

Key topics include:

- Antigen engineering strategies for improved antibody specificity and efficacy

- Workflow optimization across antibody discovery pipelines

- ADC design considerations: linker chemistry, payload selection, and conjugation approaches

- Translational challenges and industry case studies

This hybrid event welcomes both in-person and online participants. The breakfast format encourages informal exchanges and networking alongside structured scientific discussions.

With :

Jacques Fieschi holds a PhD in Immunology from Aix-Marseille University. After positions at Beckman Coulter and QIAGEN, he headed R&D at HalioDx and led the development of innovative technologies including multiplex IHC and AI-driven biomarker discovery. He is currently Chief Scientific Officer at MImAbs, leading the development of integrated workflows for therapeutic antibody and ADC discovery.

Thomas Vinos-Poyo, A biochemist by training, Thomas recently joined ACROBiosystems to support French companies developing biotherapies, including antibodies, vaccines, and cell and gene therapies.